| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa25434b47263f3342d286137a3d15ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a0c5b6f311e585fd3132f241446dea7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bdae5eb2a4e503cac9e9e7bd0e67344b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c232500f9530c62738b483232ffa8e31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bda1c083b42da0f8cc36f6a45cd91f62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b3bbffd38e7ba599c9676df46c76c06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00 |
| filingDate |
2002-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_455b768b6ee2742d18fa5d8590291ddf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59a9682109cbd3f0f7b311a08b24d70c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c4c36b57475672cbcee24a366a506a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0a323b4535116ddaf8465ac90ed8ddb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b26b99481170633b02a346891a76c21b |
| publicationDate |
2003-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03011877-A3 |
| titleOfInvention |
Process for preparing purine nucleosides |
| abstract |
The present invention provides for the preparation β-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-β-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of β to α-anomer is at least 99:1. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9045520-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8841275-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9394331-B2 |
| priorityDate |
2001-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |